TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25118042

Group type: EXPERIMENTAL
Intervention: FOX computer‐assisted fitting
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional programming methods
Number of subjects: 27
Study: 25176085

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 21700688

Group type: EXPERIMENTAL
Intervention: Chronic mountain sickness (CMS) patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy mountain dwellers (control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation in CMS patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oxygen inhalation in hypoxemic control subjects
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oxygen inhalation in normoxemic control subjects
Number of subjects: 23
Study: 21058471

Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupuncture and mild moxibustion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 60
Study: 17936534

Group type: EXPERIMENTAL
Intervention: Desloratadine and 3-hydroxydesloratadine concentrations measured using LC/MS/MS method
Number of subjects: 0
Study: 16338255

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year
Number of subjects: 12562

Group type: COMPARATOR
Intervention: Placebo in addition to aspirin for up to 1 year
Number of subjects: 12562
Study: 11888520

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g for 1 h)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 17
Study: 9489273

Group type: EXPERIMENTAL
Intervention: Repeated imaginal reliving of trauma during exposure therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High initial engagement without habituation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Moderate initial engagement without habituation
Number of subjects: 37
Study: 8919895

Group type: EXPERIMENTAL
Intervention: PCINA (0.025 mg fentanyl over 6 min)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: i.v.‐PCA (0.025 mg fentanyl bolus, lockout interval 6 min)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Customarily prescribed pain management
Number of subjects: 75
Study: 1717669

Group type: EXPERIMENTAL
Intervention: Rhenium-186(Sn)HEDP, single intravenous administration of 30-35 mCi (1110-1295 MBq)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 99mTc-methylene diphosphonate (MDP) as a radioactive placebo
Number of subjects: 0
Study: 7118361

Group type: EXPERIMENTAL
Intervention: jejunoileal bypass
Number of subjects: 134

Group type: COMPARATOR
Intervention: dietary treatment
Number of subjects: 134
Study: 31111884

Group type: EXPERIMENTAL
Intervention: Deep learning model (IVY) predicting FH pregnancy from time-lapse videos
Number of subjects: 10638

Group type: EXPERIMENTAL
Intervention: Deep learning model (IVY) across different laboratories
Number of subjects: 10638
Study: 28079136

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 2207
Study: 25428394

Group type: EXPERIMENTAL
Intervention: Iodine-125 implantation (n = 35)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional radiotherapy (n = 36)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Iodine-125 implantation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional radiotherapy and chemotherapy
Number of subjects: 71
Study: 23313208

Group type: EXPERIMENTAL
Intervention: Memokath 044TW stent
Number of subjects: 92

Group type: COMPARATOR
Intervention: Short-term urethral catheter diversion (control)
Number of subjects: 92
Study: 20971461

Group type: EXPERIMENTAL
Intervention: Skin wrinkles assessment using the Lemperle wrinkle scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin rigidity assessment using a durometer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of skin wrinkles with chronological age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of skin rigidity with time since menopause
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of weight with skin wrinkling
Number of subjects: 0
Study: 19786658

Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg orally) plus letrozole (2.5 mg orally)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Letrozole and placebo
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Lapatinib plus letrozole
Number of subjects: 219
Study: 16716491

Group type: EXPERIMENTAL
Intervention: Peritoneal non-closure
Number of subjects: 45

Group type: COMPARATOR
Intervention: Peritoneal closure
Number of subjects: 45
Study: 15550024

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg day(-1))
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg day(-1))
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 184
Study: 11501686

Group type: EXPERIMENTAL
Intervention: Adapted preventive intervention for families with parental depression; details on dosage and duration not available.
Number of subjects: 0
Study: 1626493

Group type: EXPERIMENTAL
Intervention: Digitalis (digoxin), specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6143666

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol and Metoprolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isometric and dynamic exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoprolol and Propranolol
Number of subjects: 24
Study: 30661699

Group type: EXPERIMENTAL
Intervention: Flaxseed
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 29474294

Group type: EXPERIMENTAL
Intervention: Resident-constructed, low-cost, low-fidelity pelvic model simulation training
Number of subjects: 20
Study: 27503644

Group type: EXPERIMENTAL
Intervention: EDP-239
Number of subjects: 0
Study: 23806276

Group type: EXPERIMENTAL
Intervention: Single incision group (SIG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multiple incision group (MIG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 22325974

Group type: EXPERIMENTAL
Intervention: Improvement in depression (measured by Patient Health Questionnaire‐9)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Improvement in anxiety (measured by Hospital Anxiety and Depression Scale, Anxiety subscale)
Number of subjects: 134
Study: 19732481

Group type: EXPERIMENTAL
Intervention: Comparator group (escitalopram or citalopram)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo-controlled group (escitalopram or placebo)
Number of subjects: 20
Study: 18000087

Group type: EXPERIMENTAL
Intervention: GH (150 microg/h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study: 16430017

Group type: EXPERIMENTAL
Intervention: Resin composite (Tetric Ceram)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcium aluminate cement
Number of subjects: 63
Study: 14638581

Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg/day
Number of subjects: 384
Study: 10405943

Group type: EXPERIMENTAL
Intervention: Etidronate therapy (400 mg for 14 days followed by 76 days of calcium carbonate 500 mg, repeated every 3 months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Calcium carbonate (500 to 1000 mg daily)
Number of subjects: 61
Study: 8889726

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 204

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 204
Study: 1877455

Group type: EXPERIMENTAL
Intervention: Cronassial (mixed gangliosides), 40 mg daily intramuscular injection for 4 or 8 weeks
Number of subjects: 58
Study: 3906461

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 3-mg dose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 5-mg dose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29924746

Group type: EXPERIMENTAL
Intervention: Exercise training using traditional equipment (EX)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exercise training using traditional equipment and low-dose testosterone supplementation (ExT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exercise using a combined resistance and aerobic flywheel device
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sedentary control group (CONT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All exercise groups (EX, ExT, combined device)
Number of subjects: 34
Study: 27591218

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untrained group (NoET)
Number of subjects: 30
Study: 25092781

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) with standard chemotherapy (3 mg/m2/dose, administered once in induction course 1 and once in intensification course 2)
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Standard five-course chemotherapy alone
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) with standard chemotherapy
Number of subjects: 1022
Study: 23884390

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU/d cholecalciferol for 9 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 48
Study: 21694630

Group type: EXPERIMENTAL
Intervention: Blood Draw Intervention Program
Number of subjects: 58
Study: 18699936

Group type: EXPERIMENTAL
Intervention: IVX-0142 (80 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16527229

Group type: EXPERIMENTAL
Intervention: Laser treatment according to the CAPT protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control eyes (no treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of treated vs control eyes
Number of subjects: 30
Study: 12953133

Group type: EXPERIMENTAL
Intervention: RIST (cladribine 0.11 mg/kg/day for 6 days, busulfan 4 mg/kg/day for 2 days, rabbit anti-thymocyte globulin 2.5 mg/kg/day for 2-4 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RIST
Number of subjects: 50

Group type: COMPARATOR
Intervention: CST
Number of subjects: 50
Study: 10761956

Group type: EXPERIMENTAL
Intervention: Self-selected aspirin use for at least 180 days/year
Number of subjects: 18496

Group type: COMPARATOR
Intervention: Self-selected aspirin use for 0 to 13 days/year
Number of subjects: 18496
Study: 8622072

Group type: EXPERIMENTAL
Intervention: Conservative management (tumorectomy and breast irradiation)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Lymph node irradiation
Number of subjects: 179

Group type: COMPARATOR
Intervention: No further regional treatment
Number of subjects: 179
Study: 1281030

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 52
Study: 6386275

Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Guanfacine 3 mg daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31122267

Group type: EXPERIMENTAL
Intervention: DICE method
Number of subjects: 150

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 150
Study: 30594236

Group type: EXPERIMENTAL
Intervention: Enhanced Academic Support (EAS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Business as usual support
Number of subjects: 120
Study: 27217309

Group type: EXPERIMENTAL
Intervention: Individual relationships with teachers and peers
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Classroom quality
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High-quality classrooms
Number of subjects: 111
Study: 24750038

Group type: EXPERIMENTAL
Intervention: Audible alarm condition
Number of subjects: 27

Group type: COMPARATOR
Intervention: No audible alarm condition (Control)
Number of subjects: 27
Study: 21805305

Group type: EXPERIMENTAL
Intervention: Urea-lime-treated rice straw
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 4% urea in concentrate
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Urea-lime-treated rice straw and 4% urea in concentrate
Number of subjects: 4
Study: 19851298

Group type: EXPERIMENTAL
Intervention: Oral L-citrulline (6 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18044728

Group type: EXPERIMENTAL
Intervention: Sirolimus-based immunosuppression
Number of subjects: 30

Group type: COMPARATOR
Intervention: CNI-based immunosuppression
Number of subjects: 30
Study: 15632034

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT in patients with known malignancy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT in patients without known malignancy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET/CT with SUV threshold of 2.3 in patients with known malignancy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Granulomatous diseases causing false positives in patients without known malignancy
Number of subjects: 88
Study: 12739328

Group type: EXPERIMENTAL
Intervention: Identification of high-risk patients with genetic predispositions to thrombosis
Number of subjects: 0
Study: 10482210

Group type: EXPERIMENTAL
Intervention: Ketogenic diet initiated after a 36-hour fast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory electroencephalogram
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Glucose (dextrose), 60 g/d
Number of subjects: 17
Study: 8845475

Group type: EXPERIMENTAL
Intervention: Intramuscular granisetron
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous granisetron
Number of subjects: 120
Study: 1964663

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin) administered subcutaneously at a dose of 2 X 150 anti‐Xa units/kg body weight, n = 24
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unfractionated heparin administered intravenously by continuous infusion at a dose of 450 anti‐Xa units/kg body weight daily for 10 days, n = 26
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 50
Study: 540524

Group type: EXPERIMENTAL
Intervention: Amoxapine (25 mg 3-times daily for 4 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Imipramine (25 mg 3-times daily for 4 weeks)
Number of subjects: 29
Study: 30414453

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo (historical control group)
Number of subjects: 652
Study: 28348164

Group type: EXPERIMENTAL
Intervention: Unlicensed HIV prevention technology
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Post-trial access study
Number of subjects: 382
Study: 25534231

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mini-laparotomy
Number of subjects: 120
Study: 23875721

Group type: EXPERIMENTAL
Intervention: Expressive writing (trauma focus)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Expressive writing (sexual schema focus)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Expressive writing (both interventions)
Number of subjects: 70
Study: 20976480

Group type: EXPERIMENTAL
Intervention: Spicy diet
Number of subjects: 67

Group type: COMPARATOR
Intervention: Spice-free diet (Control)
Number of subjects: 67
Study: 20027366

Group type: EXPERIMENTAL
Intervention: Tenoten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grandaxin
Number of subjects: 0
Study: 16542133

Group type: EXPERIMENTAL
Intervention: Patient‐centered Assessment and Counseling for Exercise (PACE) protocol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 96
Study: 12955426

Group type: EXPERIMENTAL
Intervention: Tirofiban therapy in addition to aspirin and heparin therapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Heparin therapy alone
Number of subjects: 83
Study: 10871828

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1b (Betaferon) 8 MIU subcutaneous every other day
Number of subjects: 304

Group type: COMPARATOR
Intervention: Interferon-beta-1a (Rebif) 6 MIU subcutaneous once a week
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 304
Study: 9378843

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.25 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous midazolam 2 mg
Number of subjects: 8
Study: 8402492

Group type: EXPERIMENTAL
Intervention: RG 12915 at 0.25 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RG 12915 at 0.50 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RG 12915 at 1.0 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RG 12915 at 2.0 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RG 12915
Number of subjects: 26
Study: 2428266

Group type: EXPERIMENTAL
Intervention: 5% Human Albumin (HA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6% Hydroxyethyl Starch (HES)
Number of subjects: 30
Study: 29024323

Group type: EXPERIMENTAL
Intervention: Oat bran (60 g)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (phenolic-low diet)
Number of subjects: 7
Study: 27302238

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment plus usual care
Number of subjects: 496

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 496
Study: 24607027

Group type: EXPERIMENTAL
Intervention: Early routine eptifibatide (n = 1,042)
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Delayed provisional eptifibatide (n = 1,024)
Number of subjects: 2066

Group type: EXPERIMENTAL
Intervention: Early routine eptifibatide
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Delayed provisional eptifibatide
Number of subjects: 2066
Study: 22892167

Group type: EXPERIMENTAL
Intervention: Trachway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Airway Scope
Number of subjects: 0
Study: 20420057

Group type: EXPERIMENTAL
Intervention: C‐SE etch (additional enamel etching)
Number of subjects: 38

Group type: COMPARATOR
Intervention: C‐SE non‐etch (without additional enamel etching)
Number of subjects: 38
Study: 18427536

Group type: EXPERIMENTAL
Intervention: Halidor preparation (100 mg, 3 times daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no halidor)
Number of subjects: 44
Study: 14707322

Group type: EXPERIMENTAL
Intervention: tizanidine (150 microg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 11331627

Group type: EXPERIMENTAL
Intervention: Low-dose exogenous FSH (75 IU/day) started on cycle day 3
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-dose exogenous FSH (75 IU/day) started on cycle day 5
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-dose exogenous FSH (75 IU/day) started on cycle day 7
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-dose exogenous FSH (75 IU/day) for all groups
Number of subjects: 40
Study: 9142562

Group type: EXPERIMENTAL
Intervention: Warm-up exercise of 25 min duration and mild intensity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warm-up exercise of 45 min duration and intense intensity
Number of subjects: 0
Study: 7515706

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of magnesium sulfate intravenously before cardiopulmonary bypass (CPB)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of magnesium soon after CPB
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of magnesium before and after CPB
Number of subjects: 140

Group type: COMPARATOR
Intervention: No magnesium (control group)
Number of subjects: 140
Study: 3070047

Group type: EXPERIMENTAL
Intervention: Multicomponent health education and skill intervention
Number of subjects: 387

Group type: COMPARATOR
Intervention: Monetary incentive for quitting
Number of subjects: 387
Study: 31318225

Group type: EXPERIMENTAL
Intervention: Individualized assessment and treatment program (IATP)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: IATP with contingency management (IATP-CM)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Motivational enhancement cognitive-behavioral treatment (MET-CBT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: MET-CBT with contingency management (MET-CBT-CM)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: IATP
Number of subjects: 198
Study: 29921409

Group type: EXPERIMENTAL
Intervention: New flowable resin‐based composite
Number of subjects: 28

Group type: COMPARATOR
Intervention: Microhybrid composite
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Proximal contact
Number of subjects: 28
Study: 27552564

Group type: EXPERIMENTAL
Intervention: (-)-epicatechin (EPI) at a total daily dose of 100mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: (+)-catechin
Number of subjects: 0
Study: 25571981

Group type: EXPERIMENTAL
Intervention: sTAP block with 0.25% bupivacaine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Local anesthetic (LA) infiltration with 0.25% bupivacaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 54
Study: 23452830

Group type: EXPERIMENTAL
Intervention: Access to medical care
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Chronic conditions
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Demographic and socioeconomic factors
Number of subjects: 1890
Study: 20590504

Group type: EXPERIMENTAL
Intervention: Intrauterine lignocaine plus vaginal misoprostol (Group I)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Only vaginal misoprostol (Group II)
Number of subjects: 49
Study: 18361183

Group type: COMPARATOR
Intervention: Gender-specific cognitive-behavioral stress management training (6 sessions)
Number of subjects: 80